POLE2

Across TCGA pan-cancer cohorts, POLE2 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of POLE2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where POLE2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types POLE2 is over-expressed in tumor.

BLCA, HNSC, and LUAD are the cancer types where POLE2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in POLE2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	All	+2.021	<.001	12	view →
HNSC	All	IV	+1.103	<.001	12	view →
LUAD	Male	III,IV	+1.970	<.001	11	view →
STAD	Female	All	+1.611	<.001	10	view →
COAD	Female	II,III,IV	+1.247	<.001	9	view →
LIHC	Male	All	+1.204	<.001	9	view →
KIRP	All	III,IV	+1.160	<.001	9	view →
KIRC	Male	IV	+0.604	<.001	9	view →
LUSC	Female	II,III,IV	+2.238	<.001	8	view →
UCEC	All	II,III,IV	+1.691	<.001	6	view →
BRCA	All	III,IV	+1.288	<.001	6	view →
READ	All	All	+0.735	.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

POLE2–BLCA

Open the BLCA breakdown →